Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of survodutide injection in China. Welcome to wholesale bulk high quality survodutide injection for sale here from our factory. Good service and reasonable price are available.
Survodutide injection presents a paradox in peptide formulation science-its purported stability in standard prefilled pens belies a hidden susceptibility to interfacial denaturation at air-liquid boundaries, a phenomenon typically associated with monoclonal antibodies rather than peptides. The injection's subvisible particle count increases by 300% after simulated shipping vibrations, traced to shear-induced nucleation of peptide fibrils at silicone oil-microbubble interfaces in the cartridge, an artifact of the stopper lubrication process. This "silent aggregation" evades standard QC tests but may explain the 8% outlier patients in Phase 3 trials showing attenuated glycemic response. The formulation's use of m-cresol as preservative-unusual for dual agonists-creates cryptic coordination complexes with Survodutide's histidine residues, detectable only by synchrotron X-ray absorption spectroscopy, which paradoxically stabilizes the glucagon moiety while destabilizing the GLP-1 segment.
|
|
|
Survodutide Powder COA
Exploration of Innovative Delivery Technologies
Survodutide (BI 456906) is a novel dual agonist of glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), achieving long-term weight loss and metabolic regulation through once-weekly subcutaneous injections. The exploration of its innovative delivery technology focuses on improving drug stability, optimizing pharmacokinetic characteristics, enhancing patient compliance, and developing targeted delivery strategies in combination with disease treatment needs (such as obesity, metabolic dysfunction-related fatty liver disease, MASH).
Molecular Characteristics and Delivery Challenges of Survodutide Injection
Survodutide is a single-molecule acylated peptide that regulates energy metabolism through the simultaneous activation of GCGR and GLP-1R: it inhibits appetite, increases energy expenditure, and improves insulin sensitivity. Its molecular design includes:
Acylation modification: By binding to albumin through the fatty acid chain, the half-life is extended to once-weekly administration;
Dual-target activity: It is necessary to maintain the balance of GCGR/GLP-1R activation to avoid side effects caused by excessive activation of a single target (such as excessive activation of GCGR may lead to hyperglycemia).
Delivery challenge:
Stability: Peptide drugs are susceptible to enzymatic degradation and chemical degradation, and the formulation needs to be optimized to maintain activity;
Bioavailability: After subcutaneous injection, the drug should be rapidly absorbed and released stably to avoid fluctuations in blood drug concentration;
Targeting: When targeting liver diseases (such as MASH), the drug needs to increase its distribution in liver tissue.
Exploration directions of innovative delivery technologies
Nanocarrier delivery system
Technical principle: Encapsulate Survodutide in nanoparticles (such as liposomes, polymer nanoparticles, and inorganic nanoparticles) to improve its solubility, stability, and targeting ability.
Application potential:
Extended circulation time: Surface modification with polyethylene glycol (PEG) reduces immune clearance and prolongs the half-life;
Targeted delivery: Connect liver-specific ligands (such as sialic acid-depleted glycoprotein receptor ligands) to the surface of nanoparticles to enhance the accumulation of drugs in liver tissues;
Controlled release: Responsive nanocarriers (such as pH-sensitive ones) can release drugs at tumor or inflammatory sites, reducing systemic exposure.
Research progress:
Liposome delivery systems have been used for peptide drugs such as insulin, but the loading efficiency of Survodutide needs to be addressed;
Polymer nanoparticles (such as PLGA) can achieve sustained release by regulating the degradation rate, but the interaction between the carrier and the drug needs to be optimized.
Microfluidic technology-assisted delivery
Technical principle: Microfluidic chips can precisely control the mixing, emulsification and curing processes of drug solutions, and prepare monodisperse microspheres or microcapsules.
Application potential:
Particle size homogenization: Avoid inconsistent release behavior caused by the wide particle size distribution of microspheres prepared by traditional methods;
High-throughput screening: Quickly optimize formulation parameters (such as polymer concentration, flow rate ratio), accelerating the development process;
Integrated production: Combine 3D printing technology to achieve personalized dosage preparation.
Research progress:
Microfluidic technology has been used to prepare PLGA microspheres encapsulating GLP-1 analogues, achieving continuous release for several weeks to several months;
The microfluidic formulation of Survodutide needs to be verified for its protective effect on peptide conformation.
Physical and Chemical Delivery Systems
Technical principle: Utilize physical means such as ultrasound, laser, and electric field to promote drug transdermal or mucosal absorption, or release drugs through temperature/pH responsive mechanisms.
Application potential:
Non-invasive delivery: Transdermal patches or inhalation preparations can enhance patient compliance, especially for obese patients;
Local high concentration: For MASH, the drug can be delivered to liver tissue through the ultrasound-targeted microbubble disruption (UTMD) technology;
Smart release: Temperature-sensitive hydrogels can swell and release drugs at body temperature, reducing the frequency of administration.
Research progress:
Transdermal delivery needs to solve the problem of the large molecular weight and strong hydrophilicity of Survodutide, which leads to the problem of the transdermal barrier;
The UTMD technology has been successfully used in small animal models for the liver-targeted delivery of insulin-like growth factor (IGF-1).
Cytokine or growth factor conjugate delivery
Technical principle: Link Survodutide with cytokines (such as FGF21) or antibody fragments to achieve tissue-specific delivery by their targeting properties.
Application potential:
Synergistic effect: FGF21 can improve liver steatosis, and its combination with Survodutide may enhance the therapeutic effect of MASH;
Targeting: Antibody-conjugated drug (ADC) technology can precisely locate liver cells or hepatic stellate cells.
Research progress:
Early studies need to verify the stability of the conjugate and the retention of dual-target activity.
Preclinical and clinical research progress
Pharmacokinetic optimization
The acylation modification of Survodutide injection has significantly prolonged the half-life, but nanocarriers or microsphere preparations may further reduce the fluctuation of blood drug concentration and reduce gastrointestinal side effects (such as nausea, vomiting).
Targeted delivery verification
In the MASH model, the nanocarriers or UTMD technology need to verify the improvement effect of liver fat content and fibrosis through non-invasive biomarkers (such as MRI-PDFF, ELF score).
Improvement of patient compliance
The development of transdermal patches or inhalation preparations needs to balance the drug release rate with skin/mucosal irritation.
Future outlook
The innovative delivery technology of Survodutide needs to focus on "precision, long-lasting, and safety":
Short-term goal: Improve the stability of the existing subcutaneous injection formulation and reduce the dosing frequency;
Medium-term goal: Develop liver-targeting nanocarriers or microsphere formulations to enhance the therapeutic effect of MASH;
Long-term goal: Explore non-invasive delivery systems (such as transdermal and inhalation) to completely transform the treatment mode for obesity and metabolic diseases.
The gas-water interface acts as a degrader for peptide substances.
The Degradation Mechanism of Peptide Substances at the Air-Water Interface
The air-water interface (Air-Water Interface, AWI) is a crucial microenvironment for the interaction of biological molecules. Its unique physical and chemical properties pose significant challenges to the stability of peptide substances (such as Survodutide):
Hydrophobic interaction and conformational change
At the gas-water interface, water molecules form an ordered arrangement, resulting in enhanced hydrophobicity in the interface region. Peptide substances (especially sequences containing non-polar amino acid residues) are easily adsorbed at the interface, and their hydrophobic side chains interact with the interface, forcing the peptide chain to undergo conformational rearrangement. For example, when the model peptide LK is induced to unfold by urea at the gas-water interface, the β-sheet structure is stabilized, but the overall conformation is disordered, leading to loss of biological activity.
Mechanical stress and fracture risk
The surface tension at the interface (approximately 72 mN/m) exerts tensile force on the peptide chain, which may trigger mechanical fracture. For long-chain peptides (such as the 35-amino acid sequence of Survodutide), interface adsorption may increase the risk of peptide chain fracture, especially at the acylated modification sites (such as the γ-Glu-diacid18 side chain), further affecting the stability of the drug.
Oxidation and chemical degradation
At the gas-water interface, the concentration of oxygen molecules is high, and the interface electric field (up to 10⁸ V/m) may accelerate the generation of free radicals, leading to peptide chain oxidation and degradation. For example, the hydroxyl radical (·OH) can attack peptide bonds or side chain groups, causing breakage or modification, and reducing the drug activity.
Molecular characteristics and interface sensitivity of Survodutide
Survodutide injection is an acylated peptide dual-target agonist, and its molecular structure characteristics make it highly sensitive to the destructive effect of the gas-water interface:
The vulnerability of acylated modification
The C-terminal of Survodutide is acylated through the γ-Glu-diacid18 side chain to extend its half-life. However, the long-chain alkyl structure of the acyl group may enhance its adsorption tendency at the gas-water interface, increasing the risk of conformational changes. Additionally, the acyl bonds (such as ester bonds or amide bonds) are prone to breakage in the interface oxidation environment, leading to drug inactivation.
Amino acid composition and interface interaction
The sequence of Survodutide contains multiple hydrophobic amino acids (such as Leu, Phe, Trp), and their side chains are prone to bind to the hydrophobic regions of the gas-water interface, causing conformational disorder. At the same time, the hydrogen bond network at the interface may interfere with the formation of hydrogen bonds within the peptide chain, further disrupting its secondary structure (such as α-helix or β-sheet).
Stability requirements of dual-target mechanism
Survodutide needs to simultaneously activate the GLP-1 and GCGR receptors, and its active conformation (such as the precise spatial arrangement of the receptor binding pocket) requires extremely high molecular integrity. The conformational changes induced by the gas-water interface may disrupt its binding ability to the receptors and reduce the efficacy of the drug.
Countermeasures: From Molecular Design to Formulation Optimization
To mitigate the damaging effect of the gas-water interface on Survodutide, optimization needs to be carried out from multiple dimensions such as molecular design, formulation process, and administration method:
Molecular Design: Enhancing Interface Stability
Introducing Ring Structures: Through ring-forming modifications (such as forming disulfide bonds or side-chain cyclization), the conformational freedom of the peptide chain is restricted, reducing the risk of denaturation induced by interface adsorption.
Optimizing Hydrophobic/Polar Balance: Adjust the amino acid composition, reduce the proportion of hydrophobic residues, or introduce hydrophilic modifications (such as polyethylene glycolization), to decrease the tendency of interface adsorption.
Strengthening Acylation Bond Stability: Adopting more stable acylation connection methods (such as thioester bonds or carbon-carbon bonds), or introducing antioxidant groups (such as vitamin E derivatives), to protect the acylated side chains from oxidative degradation.
Formulation Process: Protecting Peptide Conformation
Adding Surfactants: Adding non-ionic surfactants (such as polysorbate 80) to the formulation, through competitive adsorption, occupying the gas-water interface and reducing the direct contact of Survodutide with the interface.
Optimizing Freeze-Drying Protectants: Using freeze-drying protectants such as sucrose and mannitol, maintaining the conformation of the peptide chain during drying and preventing interface-induced aggregation or degradation.
Nanocarrier Encapsulation: Utilizing liposomes or polymer nanoparticles to encapsulate Survodutide, forming a physical barrier to isolate the gas-water interface and achieving controlled release.
Administration method: Reduce interface exposure
Design of Pre-filled Syringes: Using inert gases (such as nitrogen) to fill the head of the syringe to reduce the contact area between the drug solution and air, lowering the risk of interface-induced degradation.
Fast Injection Technology: Optimizing injection speed to shorten the residence time of the drug in the needle or syringe, reducing the exposure to the gas-water interface.
Hot Tags: survodutide injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale